Why It’s Important to Have Hard Conversations in Breast Cancer Care
CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.
Read More
Ongoing Trials Aim to Advance HER2-Negative Breast Cancer Treatment
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.
Targeted Axillary Dissection Offers a Precise Option in Breast Cancer
Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.
Watch
Guiding Patients Through Shared Decision-Making in Breast Cancer Care
Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.
Understanding the Best Practices Associated With CDK4/6 Therapy in Breast Cancer
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
COSMIC-313 Trial Lead Breaks Down Treatment Intensification in RCC
Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.
Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.
Real-World Data Confirms Safety of Bavencio and Inlyta in Advanced RCC
In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.
Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.
Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC
Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.
UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.
Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.
Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC
Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.
An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset
Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.
Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma
Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.
Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.
FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC
Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.
Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Padcev Significantly Improves OS in Real-World Urothelial Carcinoma
Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall survival outcomes.
Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions
Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.
High Omega-3 Diet With Fish Oil Reduces Ki-67 Index in Prostate Cancer
Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.
Neuropathy, Rash, Hyperglycemia Linked to PFS in Urothelial Carcinoma
Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.
Padcev May Be Safe in Older Patients With Bladder Cancer
Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.
Estrogen Patches with ARPIs Found to Be Safe, Effective in Prostate Cancer
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.
Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume
Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death by 46%, per ARANOTE data.
Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.
